tiprankstipranks
Trending News
More News >
HYTN Innovations Inc (TSE:HYTN)
:HYTN

HYTN Innovations Inc (HYTN) AI Stock Analysis

Compare
4 Followers

Top Page

TS

HYTN Innovations Inc

(HYTN)

Rating:49Neutral
Price Target:
C$0.00
▼(-100.00%Downside)
HYTN Innovations Inc. faces significant financial challenges, with a negative financial performance score due to profitability and cash flow issues. However, recent corporate events suggest potential for international growth, which positively impacts the overall score.

HYTN Innovations Inc (HYTN) vs. iShares MSCI Canada ETF (EWC)

HYTN Innovations Inc Business Overview & Revenue Model

Company DescriptionHYTN Innovations Inc (HYTN) is a company that operates within the cannabis industry. It specializes in the research, development, and production of cannabis-infused beverages. The company focuses on providing high-quality, innovative products aimed at enhancing consumer experiences with cannabis in a socially responsible and legally compliant manner.
How the Company Makes MoneyHYTN Innovations Inc makes money primarily through the sale of its cannabis-infused beverage products. The company's key revenue streams include direct sales to consumers through retail channels and partnerships with licensed cannabis retailers and distributors. Additionally, HYTN may generate income through strategic partnerships and collaborations with other companies in the cannabis industry, leveraging its expertise in product development and innovation to expand its market presence and reach.

HYTN Innovations Inc Financial Statement Overview

Summary
HYTN Innovations Inc. is facing significant financial challenges with negative profitability, cash flow issues, and a concerning balance sheet marked by negative equity. Despite slight revenue growth, the company must address liquidity and solvency risks.
Income Statement
40
Negative
HYTN Innovations Inc. has shown some revenue growth, but profitability remains a concern with negative net income, EBIT, and EBITDA margins. The gross profit margin is slightly positive, indicating potential for future improvement, but the net profit margin remains deeply negative.
Balance Sheet
30
Negative
The company's balance sheet shows a negative equity position, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is also negative, highlighting potential solvency issues.
Cash Flow
35
Negative
HYTN's cash flow statement reveals negative free cash flow and operating cash flow, suggesting cash burn. The company relies heavily on financing activities, which may not be sustainable long-term. There is no free cash flow growth, and the ratios to net income are challenging to assess with negative figures.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2019
Income Statement
Total Revenue849.66K851.49K763.46K696.36K0.000.00
Gross Profit50.19K287.44K91.85K121.65K0.00-1.12K
EBITDA-6.55M-6.26M-1.45M-9.88M-745.51K-310.99K
Net Income-6.91M-6.61M-2.33M-17.38M-959.48K-311.66K
Balance Sheet
Total Assets2.47M2.38M2.58M3.79M2.76M507.25K
Cash, Cash Equivalents and Short-Term Investments15.58K256.58K187.56K1.03M264.06K271.16K
Total Debt788.02K793.56K919.74K887.22K2.58M41.98K
Total Liabilities2.63M2.56M2.27M1.71M2.77M18.41K
Stockholders Equity-164.33K-172.97K314.72K2.07M-8.88K488.85K
Cash Flow
Free Cash Flow-1.37M-804.21K-1.18M-2.38M-1.67M-409.37K
Operating Cash Flow-1.36M-783.36K-1.18M-2.16M-693.52K-311.08K
Investing Cash Flow173.91K162.67K-4.10K2.19M-1.02M-98.29K
Financing Cash Flow1.16M689.71K346.17K727.93K1.80M700.53K

HYTN Innovations Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.21
Price Trends
50DMA
0.21
Positive
100DMA
0.23
Negative
200DMA
0.26
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
50.15
Neutral
STOCH
23.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HYTN, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.21, and below the 200-day MA of 0.26, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.15 is Neutral, neither overbought nor oversold. The STOCH value of 23.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HYTN.

HYTN Innovations Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
C$18.92M-549.30%-8.04%4.04%
TSBR
50
Neutral
C$26.35M-46.36%9.98%-80.44%
49
Neutral
C$2.92B2.03-80.91%2.68%12.55%-24.32%
49
Neutral
C$19.68M-9999.00%68.80%-204.31%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:HYTN
HYTN Innovations Inc
0.21
-0.15
-41.67%
TSE:BR
Big Rock Brewery
1.10
-0.16
-12.70%
TSE:LSPK
LifeSpeak
0.32
-0.07
-17.95%

HYTN Innovations Inc Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
HYTN Innovations Secures First International Order for GMP Vape Cartridges
Positive
Jun 11, 2025

HYTN Innovations Inc. has received its first international purchase order for Good Manufacturing Practices (GMP) cannabis vape cartridges, marking a significant milestone in its collaboration with SNDL. This order, which involves 1000 one-gram live resin vape cartridges, is set to be exported to the United Kingdom, pending permit approvals, and underscores HYTN’s commitment to quality and its capability to serve regulated international markets. This development highlights the company’s growing influence in the global pharmaceutical cannabis market and its dedication to expanding its product portfolio with high-quality GMP cannabis products.

Business Operations and StrategyRegulatory Filings and Compliance
HYTN Innovations Secures GMP Certification for Key International Markets
Positive
Apr 3, 2025

HYTN Innovations Inc. has received Good Manufacturing Practices (GMP) certificates from Health Canada for its manufacturing facility in Kelowna, confirming compliance for the United States, Bermuda, and Israel. These certifications enhance HYTN’s ability to support drug registrations, facilitate clinical trials, and offer contract manufacturing for cannabis and psilocybin-based pharmaceuticals, positioning the company for international growth and strengthening its leadership in high-quality manufacturing practices.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025